Subchronic inhalation of a novel electronic nicotine delivery system formulation and its corresponding base formulation
Human & Experimental Toxicology · 2024
DOI: 10.1177/09603271241248631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human & Experimental Toxicology, 2024. Verfasst von Guy Lalonde und 5 weiteren Autor:innen. Beteiligte Einrichtung: Juul Labs, Inc., Washington, DC, USA. Hauptthemen laut MEDLINE: Electronic Nicotine Delivery Systems, Nicotine. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Juul Labs, Inc..
Abstract (Originalsprache)
Background
Fresh Menthol 3% Nicotine (FM3) is a novel JUUL e-liquid formulation. Its potential toxicity and that of the corresponding base formulation relative to a filtered air (FA) control was studied in a subchronic inhalation study conducted in general accordance with OECD 413.
Methods
Aerosols generated with an intense puffing regime were administered to rats in a nose-only fashion at 1400 µg aerosol collected mass/L on a 6 hour/day basis for 90 days with a 42-day recovery. Exposure atmospheres met target criteria. Systemic exposure was confirmed by plasma measurement of nicotine.
Results
No test article-related mortality, clinical signs (other than reversible lower body weight gains in males), clinical pathology or gross findings were noted during this study. No microscopic lesions related to base formulation exposure were identified. Minimal microscopic lesions were observed in the FM3 6-hour exposure group. Microscopic lesions observed in the FM3 6-hour exposure group comprised only minimal laryngeal squamous metaplasia in one male and one female animal. No microscopic lesions related to FM3 exposure remained after the recovery period.
Conclusion
Exposure atmosphere characterization indicated that conditions were achieved to permit thorough assessment of test articles and results indicate a low order of toxicity for the FM3 Electronic nicotine delivery systems (ENDS) formulation and its base formulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Juul Labs, Inc., Washington, DC, USA.
- Protavio Ltd, Attiki, Greece.
- AmplifyBio, West Jefferson, OH, USA.
- Kozmin Consulting LLC, Flat Rock, NC, USA.
ORCID-Profile: Guy Lalonde, Tessa R Moir-Savitz, Michael J Oldham
Förderung
- Juul Labs, Inc.
Zitieren
APA
Lalonde, G., Tsolakos, N., Moir-Savitz, T. R., Easley, A. M., Gaworski, C. L., & Oldham, M. J. (2024). Subchronic inhalation of a novel electronic nicotine delivery system formulation and its corresponding base formulation. Human & Experimental Toxicology. https://doi.org/10.1177/09603271241248631
Vancouver
Lalonde G, Tsolakos N, Moir-Savitz TR, Easley AM, Gaworski CL, Oldham MJ. Subchronic inhalation of a novel electronic nicotine delivery system formulation and its corresponding base formulation. Human & Experimental Toxicology. 2024. doi:10.1177/09603271241248631
BibTeX
@article{Lalonde2024,
author = {Lalonde, Guy and Tsolakos, Nikos and Moir-Savitz, Tessa R and Easley, Alex M and Gaworski, Charles L and Oldham, Michael J},
title = {Subchronic inhalation of a novel electronic nicotine delivery system formulation and its corresponding base formulation},
journal = {Human & Experimental Toxicology},
year = {2024},
doi = {10.1177/09603271241248631}
}
EUVIMED